

Maura Corsetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8597149/publications.pdf>

Version: 2024-02-01

100
papers

3,552
citations

136950

32
h-index

149698

56
g-index

101
all docs

101
docs citations

101
times ranked

3180
citing authors

#	ARTICLE	IF	CITATIONS
1	Irritable bowel syndrome. <i>Lancet</i> , The, 2020, 396, 1675-1688.	13.7	348
2	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 31-59.	4.0	224
3	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. <i>Gut</i> , 2021, 70, 1214-1240.	12.1	212
4	Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2019, 156, 46-58.e7.	1.3	162
5	Impact of Coexisting Irritable Bowel Syndrome on Symptoms and Pathophysiological Mechanisms in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2004, 99, 1152-1159.	0.4	145
6	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105812.	4.0	137
7	Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. <i>Gastroenterology</i> , 2004, 127, 1058-1066.	1.3	119
8	First translational consensus on terminology and definitions of colonic motility in animals and humans studied by manometric and other techniques. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 559-579.	17.8	108
9	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2677-2684.	3.3	92
10	Gastrointestinal behavior of nano- and micro-sized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 77, 40-47.	4.0	82
11	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. <i>International Journal of Pharmaceutics</i> , 2017, 519, 79-97.	5.2	81
12	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017, 5, 773-788.	3.8	81
13	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 1</i>	12.1	80
14	Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1425-1435.	2.4	68
15	Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 265-274.	3.7	63
16	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 63, 233-242.	4.0	63
17	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	3.8	62
18	Prevalence of Genetic Hemochromatosis in a Cohort of Italian Patients with Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1998, 128, 370.	3.9	61

#	ARTICLE	IF	CITATIONS
19	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <i>United European Gastroenterology Journal</i> , 2021, 9, 287-306.	3.8	60
20	Pan-Colonic Pressurizations Associated With Relaxation of the Anal Sphincter in Health and Disease: A New Colonic Motor Pattern Identified Using High-Resolution Manometry. <i>American Journal of Gastroenterology</i> , 2017, 112, 479-489.	0.4	58
21	Prevalence and impact of self-reported irritable bowel symptoms in the general population. <i>United European Gastroenterology Journal</i> , 2019, 7, 307-315.	3.8	56
22	British Society of Gastroenterology guidelines on the management of functional dyspepsia. <i>Gut</i> , 2022, 71, 1697-1723.	12.1	54
23	Endogenous motilin, but not ghrelin plasma levels fluctuate in accordance with gastric phase III activity of the migrating motor complex in man. <i>Neurogastroenterology and Motility</i> , 2015, 27, 63-71.	3.0	53
24	Effect of Transoral Incisionless Fundoplication on Symptoms, PPI Use, and pH-Impedance Refluxes of GERD Patients. <i>World Journal of Surgery</i> , 2010, 34, 750-757.	1.6	51
25	Intragastric infusion of denatonium benzoate attenuates interdigestive gastric motility and hunger scores in healthy female volunteers. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 580-588.	4.7	51
26	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2904-2912.	3.3	43
27	<sc>FDA</sc> and <sc>EMA</sc> end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?. <i>Neurogastroenterology and Motility</i> , 2013, 25, 453-457.	3.0	41
28	Intragastric infusion of the bitter tastant quinine suppresses hormone release and antral motility during the fasting state in healthy female volunteers. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13171.	3.0	41
29	Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 49-56.	4.4	40
30	Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. <i>United European Gastroenterology Journal</i> , 2022, 10, 556-584.	3.8	40
31	The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 459-473.	8.1	37
32	Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1327-1335.	3.3	35
33	Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. <i>United European Gastroenterology Journal</i> , 2013, 1, 7-20.	3.8	33
34	The global impact of IBS: time to think about IBS-specific models of care?. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 727-736.	3.2	33
35	The role of tension receptors in colonic mechanosensitivity in humans. <i>Gut</i> , 2004, 53, 1787-1793.	12.1	31
36	Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1354-1370.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Modern Management of Irritable Bowel Syndrome: More Than Motility. <i>Digestive Diseases</i> , 2016, 34, 566-573.	1.9	28
38	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
39	When all seems lost: management of refractory constipation—Surgery, rectal irrigation, percutaneous endoscopic colostomy, and more. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13352.	3.0	25
40	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14050.	3.0	25
41	Naloxegol, a new drug for the treatment of opioid-induced constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 399-406.	1.8	24
42	The quest for biomarkers in IBS—where should it lead us?. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1669-1676.	3.0	21
43	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	3.0	21
44	Development, content validity, and cross-cultural adaptation of a patient-reported outcome measure for real-time symptom assessment in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13244.	3.0	20
45	Evaluation of Rectal Sensory and Motor Function by Means of the Electronic Barostat After Stapled Hemorrhoidopexy. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1255-1260.	1.3	19
46	Perceptual sensitivity and response bias during rectal distension in patients with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2005, 17, 541-547.	3.0	18
47	Novel pharmacological therapies for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 807-815.	3.0	18
48	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105517.	4.0	18
49	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	3.0	17
50	Magnetic Resonance Imaging of the Rectum During Distension. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1220-1227.	1.3	16
51	Manometric evaluation of anorectal function in patients treated with neoadjuvant chemoradiotherapy and total mesorectal excision for rectal cancer. <i>Digestive and Liver Disease</i> , 2017, 49, 91-97.	0.9	15
52	Naloxegol: The first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. <i>Drugs of Today</i> , 2015, 51, 479.	1.1	15
53	New pharmacological treatment options for chronic constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 927-941.	1.8	13
54	New therapeutic options for IBS: the role of the first in class mixed μ -opioid receptor agonist and δ -opioid receptor antagonist (mudelta) eluxadolone. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 285-292.	3.0	13

#	ARTICLE	IF	CITATIONS
55	Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14123.	3.0	13
56	Tegaserod: a new 5-HT ₄ agonist in the treatment of irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1211-1218.	1.8	12
57	Are Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome Useful in Clinical Practice?. <i>Digestion</i> , 2004, 70, 207-209.	2.3	12
58	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 517.	1.6	12
59	High-resolution manometry reveals different effect of polyethylene glycol, bisacodyl, and prucalopride on colonic motility in healthy subjects: An acute, open label, randomized, crossover, reader-blinded study with potential clinical implications. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14040.	3.0	12
60	Rectal Distensibility and Symptoms After Stapled and Milligan-Morgan Operation for Hemorrhoids. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 2245-2251.	1.7	11
61	Naloxegol for the treatment of opioid-induced constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 855-861.	3.0	10
62	Will MRI of gastrointestinal function parallel the clinical success of cine cardiac MRI?. <i>British Journal of Radiology</i> , 2019, 92, 20180433.	2.2	10
63	Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?. <i>Current Opinion in Pharmacology</i> , 2018, 43, 53-58.	3.5	10
64	Patient-Specific Stress-Abdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00209.	2.5	10
65	Manometric demonstration of duodenal/jejunal motor function consistent with the duodenal brake mechanism. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13835.	3.0	9
66	The management of functional dyspepsia in clinical practice: what lessons can be learnt from recent literature?. <i>F1000Research</i> , 2017, 6, 1778.	1.6	8
67	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. <i>PLoS ONE</i> , 2020, 15, e0241441.	2.5	8
68	How to improve drug development for functional disorders. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 787-796.	2.4	7
69	Influence of nitric oxide synthase inhibition on the motility and sensitivity of distal colon in man. <i>Neurogastroenterology and Motility</i> , 2013, 25, e256-62.	3.0	7
70	Development of Fixed Dose Combination Products-Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. <i>AAPS Journal</i> , 2019, 21, 75.	4.4	7
71	The tapestry of reflux syndromes: translating new insight into clinical practice. <i>British Journal of General Practice</i> , 2021, 71, 470-473.	1.4	6
72	Letter: limitations of defecography among patients with refractory constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 111-112.	3.7	5

#	ARTICLE	IF	CITATIONS
73	Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?. <i>F1000Research</i> , 2019, 8, 257.	1.6	5
74	Elobixibat. Ileal sodium-dependent bile acid transporter (IBAT) inhibitor agent for constipation. <i>Drugs of the Future</i> , 2012, 37, 475.	0.1	5
75	Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of <sc>PPI</sc> "resistance" a multidisciplinary perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1492-1500.	3.7	5
76	Evaluation of basophil activation test in suspected food hypersensitivity. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 279-285.	1.5	4
77	Seated anorectal manometry during simulated evacuation: A physiologic exercise or a new clinically useful diagnostic test?. <i>Neurogastroenterology and Motility</i> , 2020, 32, e14001.	3.0	4
78	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. <i>Pharmaceutics</i> , 2022, 14, 801.	4.5	4
79	Ghrelin Agonists as Emerging Prokinetic Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2320-2322.	4.4	3
80	Defecatory urge increases cognitive control and intertemporal patience in healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13600.	3.0	3
81	The MRI colonic function test: Reproducibility of the Macrogol stimulus challenge. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13942.	3.0	3
82	Managing irritable bowel syndrome in primary care. <i>Practitioner</i> , 2015, 259, 21-4, 2-3.	0.3	3
83	Rectal wall exclusion: a new complication after STARR procedure. <i>Colorectal Disease</i> , 2010, 12, 702-703.	1.4	2
84	1021 Pan-Colonic Pressurizations Associated With Relaxation of the Anal Sphincter in Man: A Highly Prevalent Colonic Motor Event Identified Using High-Resolution Manometry and Associated With Feeling and Desire to Evacuate Gas. <i>Gastroenterology</i> , 2015, 148, S-192.	1.3	2
85	Su1584 Colonic Motor Responses to a Meal and to Bisacodyl, Evaluated by High-Resolution Manometry (HRM), Differ Between Laxative-Refractory Slow Transit Constipation With or Without Pain. <i>Gastroenterology</i> , 2016, 150, S533-S534.	1.3	2
86	Reproducibility of sensations induced by rectal distention in patients with irritable bowel syndrome: Role of rectal contractions. <i>Gastroenterology</i> , 2000, 118, A842.	1.3	1
87	Sa2056 Comparison of the Effect of Prucalopride, Sodium Picosulfate and Placebo on Rectal Motor and Sensory Response to Distension Assessed by Electronic Barostat in Healthy Subjects. <i>Gastroenterology</i> , 2014, 146, S-365.	1.3	1
88	83 Effect of the Esophyx Device for Endoluminal Fundoplication On Symptoms, Esophageal Manometry and pH-Impedance of Patients with Gastro-Esophageal Reflux. <i>Gastroenterology</i> , 2008, 134, A-13-A-14.	1.3	0
89	Response to: "First case of rectal inclusion cyst after stapled haemorrhoidopexy (PPH)"™. <i>Colorectal Disease</i> , 2009, 11, 104-104.	1.4	0
90	548 Combined Multichannel Intraluminal Impedance and pH Esophageal Testing Versus pH Alone for Diagnosing Gastro-Esophageal Reflux: A Study On Italian Patients Off Therapy. <i>Gastroenterology</i> , 2009, 136, A-85.	1.3	0

#	ARTICLE	IF	CITATIONS
91	T1253 Sumatriptan Inhibits the Colonic Response to Intragastric, But Not Intraduodenal, Nutrient Administration. <i>Gastroenterology</i> , 2009, 136, A-532.	1.3	0
92	W1079 Effect of Endoscopic Fundoplication With EsophyX Device on Proton Pump Inhibitors Usage in a Single Third Level Italian Care Center. <i>Gastroenterology</i> , 2010, 138, S-647.	1.3	0
93	News from the editors of <i>Neurogastroenterology and Motility</i> . <i>Neurogastroenterology and Motility</i> , 2017, 29, e13169.	3.0	0
94	Rectal area as surrogate measure of rectal emptying during MR defecography. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13634.	3.0	0
95	Exciting news from the editors of <i>Neurogastroenterology and Motility</i> . <i>Neurogastroenterology and Motility</i> , 2019, 31, e13622.	3.0	0
96	Investigation of anorectal motility. , 2020, , 399-412.		0
97	Investigation of colonic motility. , 2020, , 413-420.		0
98	In Silico Food-Drug Interaction: A Case Study of Eluxadoline and Fatty Meal. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9127.	4.1	0
99	Gastric emptying. <i>Nuclear Medicine Communications</i> , 2020, 41, 497-498.	1.1	0
100	Esophageal 24-Hour pH-Metry after Esophageal Manometry Facilitated by a New Medical Device, A Mini-Overtube. <i>Open Medical Devices Journal</i> , 2009, 1, 11-13.	0.3	0